PTC-028 是一种口服有效的干细胞因子 BMI-1 的抑制剂，可用于治疗卵巢癌。PTC-028 选择性地抑制癌细胞，而正常细胞不受影响。PTC-028 对 BMI-1 的作用可诱导 caspase 介导的细胞凋亡 (apoptosis)。
CAS：1782970-28-8
分子式：C19H12F5N5
分子量：405.32
纯度：98%
存储：Store at -20°C

Background:

PTC-028 is an orally bioavailable inhibitor of stem cell factor BMI-1 in ovarian cancer. PTC-028 selectively inhibits cancer cells whereas normal cells remain unaffected. Depletion of BMI-1 by PTC-028 induces caspase-mediated apoptosis[1]. BMI-1[1]

PTC-028 (25-500 nM; 48 hours) significantly decreases CP20, OVCAR4 and OV90 epithelial ovarian cancer cells viability. However, in normal ovarian surface epithelial cells (OSE) and fallopian tube epithelial cells (FTE) cells, up to 500 nM treatment with PTC-028 for 48 hours has minimal effect (